Efficacy of leukotriene receptor antagonist in chronic urticaria. A double‐blind, placebo‐controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid

@article{Pacor2001EfficacyOL,
  title={Efficacy of leukotriene receptor antagonist in chronic urticaria. A double‐blind, placebo‐controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid},
  author={Maria Luisa Pacor and Gabriele Di Lorenzo and Roberto Corrocher},
  journal={Clinical \& Experimental Allergy},
  year={2001},
  volume={31}
}
Background The cause and pathogenesis of chronic urticaria are still poorly understood. IgE‐independent reactions, are common in adult patients with chronic urticaria, who have daily spontaneous occurrence of weals. H1‐receptor antagonists (antihistamines) are the major class of therapeutic agents used in the management of urticaria and angioedema. Nevertheless, chronic urticaria is often difficult to treat and may not be controlled by antihistamines alone. It has been postulated that mediators… Expand
The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study.
  • Z. Erbagci
  • Medicine
  • The Journal of allergy and clinical immunology
  • 2002
TLDR
The present study results suggest that montelukast might be an effective and safe therapeutic agent in the treatment of refractory CIU. Expand
Leukotriene receptor antagonists in monotherapy or in combination with antihistamines in the treatment of chronic urticaria: a systematic review
TLDR
Evidence for the effectiveness of zafirlukast and the 5-lipoxygenase inhibitor, zileuton, in chronic urticaria is mainly anecdotal, and there is anecdotal evidence of effectiveness of antileukotrienes in primary cold Urticaria, delayed pressure urticarias and dermographism. Expand
Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs.
TLDR
Sensitivity to NSAIDs in CIU is associated with overproduction of cysteinyl leukotrienes and mast cell activation and most likely depends on inhibition of cyclooxygenase 1. Expand
The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria
TLDR
Montelukast may be worth trying for patients with chronic idiopathic urticaria, when the condition is not sufficiently controlled with histamine H1-receptor antagonists. Expand
Leukotriene receptor antagonists for chronic urticaria: a systematic review
TLDR
LTRA are effective add-on therapy to anti-histamines, and their use in patients responding poorly to antihistamines is justifiable, but further well designed randomized controlled trials with clear and standardized outcome measures are needed to determine the role of LTRA in chronic urticaria. Expand
Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria.
TLDR
The results of this comparative study demonstrate that desloratadine is highly effective for the treatment of patients affected by moderate CIU, and the regular combined therapy of deslor atadine plus montelukast does not seem to offer a substantial advantage with respect to deslorAtadine as monotherapy. Expand
The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results.
TLDR
The results of this study indicate that only patients with autoimmune (ASST positive) chronic urticaria refractory to H(1)-antagonist monotherapy might benefit from the addition of the leukotriene D(4)-receptor antagonist zafirlukast to their treatment regimen. Expand
Allergic dermatosis and urticaria
TLDR
The two recent placebo-controlled, double-blinded studies discussed in this report have provided further insights into the efficacy of LTRAs as montherapy or in combination with desloratadine in the management of CIU. Expand
Leukotriene receptor antagonist drugs: A tool
TLDR
Because of safety and good tolerability of montelukast as early as six-month-old, this review could represent an opportunity to encourage researchers to publish controlled trials using antileukotrienes in children with CU. Expand
Is there a role for antileukotrienes in urticaria?
TLDR
Evidence for the effectiveness of zafirlukast and the 5‐lipoxygenase inhibitor, zileuton, in chronic urticaria is mainly anecdotal and no evidence exists for other physical urticarias, including cholinergic, solar and aquagenic urticARIas, vibratory angio‐oedema, and exercise‐induced anaphylaxis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 46 REFERENCES
Cetirizine : A Reappraisal of its Pharmacological Properties and Therapeutic Use in Selected Allergic Disorders.
TLDR
Cetirizine 10 mg/day appears to be as effective as conventional dosages of other established antihistamines such as astemizole, hydroxyZine, ketotifen, loratadine or terfenadine in relieving symptoms of these disorders, and is associated with a significantly lower incidence of sedation than hydroxyzine. Expand
Urticaria. Recognition, causes and treatment.
TLDR
For the majority of patients with chronic idiopathic urticaria, nonsedating antihistamines are the mainstay of treatment, and recent work on circulating histamine releasing autoantibodies suggests that there is scope for more aggressive immunosuppression in selected patients. Expand
A double‐blind, placebo‐controlled comparison of treatment with fluticasone propionate and levocabastine in patients with seasonal allergic rhinitis
TLDR
Unlike levocabastine, FPANS significantly attenuates nasal eosinophilia during pollen exposure, a feature which may explain its therapeutic efficacy. Expand
Montelukast causes prolonged, potent leukotriene D4‐receptor antagonism in the airways of patients with asthma
TLDR
Results indicate that montelukast is a highly potent and long‐lasting antagonist of LTD4‐induced bronchoconstriction in patients with asthma. Expand
Adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs.
TLDR
Emerging clinical syndromes help to guide the clinicians through the maze of symptoms and often provide a unique insight into the mechanism of basic disease. Expand
A follow‐up study of patients with recurrent urticaria and hypersensitivity to aspirin, benzoates and azo dyes
TLDR
Most patients with recurrent urticaria and angio‐oedema who became totally free of symptoms did not continue with the diet, while most of the patients who considered themselves much better found that it was necessary to continue on the recommended diet. Expand
The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.
TLDR
The effects of an inhibitor of 5-lipoxygenase, zileuton, was examined in a group of eight asthmatic patients with known sensitivity to ASA accompanied by LTE4 hyperexcretion to confirm ASA sensitivity and an increase in urinary LTE4 after ASA ingestion. Expand
Urticaria and asthma induced by food-and-drug additives in patients with aspirin hypersensitivity.
Abstract Seven of 8 recently investigated aspirin-sensitive patients reacted with asthma, urticaria, or both after 1 to 2 mg. of the azobenzene dye, tartrazine. Tartrazine is commonly used as a foodExpand
The effect of the oral leukotriene antagonist, ICI 204,219, on leukotriene D4 and histamine-induced cutaneous vascular reactions in man.
TLDR
The results raise the possibility for additional investigation of the antagonistic effect of ICI 204,219 in nonallergic and allergic cutaneous diseases, and the role of leukotrienes as potentially important mediators in immediate-type reactions. Expand
Acute and chronic urticaria and angioedema.
  • N. Soter
  • Medicine
  • Journal of the American Academy of Dermatology
  • 1991
TLDR
Patients with urticaria and/or angioedema can be classified based on pathophysiologic mechanisms into those with IgE-dependent or complement-mediated immunologic disorders, those with nonimmunologic disorders in which there is a direct effect on the mast cell or on arachidonic acid metabolism, and those whose condition is idiopathic. Expand
...
1
2
3
4
5
...